首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 15 毫秒
1.
目的研究瘦素与非酒精性脂肪肝(NAFL)肝纤维化发生与发展的关系。方法用ELISA方法测定30例NAFL患者血清瘦素水平,20例健康人作为对照组,同时检测NAFL患者的血清肝纤维化指标HA、LN、pcⅢ,对血清瘦素与肝纤维化指标的关系进行分析。结果NAFL患者血清瘦素水平明显高于对照组,轻、中、重度非酒精性脂肪肝患者血清瘦素水平依次增高.差异有显著性(p〈0.05);中、重度非酒精性脂肪肝患者血清瘦素水平与肝纤维化血清学指标呈正相关。结论瘦素在NAFL发病中具有独立的致病作用,并可能是NAFL肝纤维化形成中重要的调控因子之一。  相似文献   

2.
非酒精性脂肪肝患者血清瘦素水平与肝纤维化关系研究   总被引:2,自引:0,他引:2  
目的研究瘦素与非酒精性脂肪肝(NAFL)肝纤维化发生与发展的关系。方法用ELISA方法测定30例NAFL患者血清瘦素水平,20例健康人作为对照组,同时检测NAFL患者的血清肝纤维化指标HA、LN、PCⅢ,对血清瘦素与肝纤维化指标的关系进行分析。结果NAFL患者血清瘦素水平明显高于对照组,轻、中、重度非酒精性脂肪肝患者血清瘦素水平依次增高,差异有显著性(p<0.05);中、重度非酒精性脂肪肝患者血清瘦素水平与肝纤维化血清学指标呈正相关。结论瘦素在NAFL发病中具有独立的致病作用,并可能是NAFL肝纤维化形成中重要的调控因子之一。  相似文献   

3.
目的探讨血清铁蛋白(sF)水平在成人非酒精性脂肪性肝病(NAFLD)患者中的临床意义。方法对入选的158例健康体检人群,进行血清铁蛋白、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL—C)、低密度脂蛋白(LDL—C)、空腹血糖(FBG)、血尿酸(UA)、谷草转氨酶(AST)及谷丙转氨酶(ALT)等各指标检测及肝脏超声检查,根据肝脏超声结果分为NAFLD组(68例)及正常对照组(90例),比较两组间血清铁蛋白水平及血脂、血糖、尿酸、转氨酶等生化指标情况。结果NAFLD组中血清铁蛋白水平及甘油三酯、尿酸、转氨酶明显高于对照组,而高密度脂蛋白明显低于对照组(p〈0.01);进一步相关性分析显示.血清铁蛋白与谷草转氨酶及谷丙转氨酶显著相关(r=0.260、0.299,P〈0.01)。结论血清铁蛋白水平的升高可能提示NAFLD患者肝损的一个有效指标,并在NAFLD的进展过程中可能起一定的作用。  相似文献   

4.
Obesity and Nonalcoholic Fatty Liver Disease   总被引:4,自引:0,他引:4  
With the increasing prevalence of obesity and type 2 diabetes mellitus in the general population, nonalcoholic fatty liver disease (NAFLD) has become a common diagnosis in clinical practice. Insulin resistance and oxidative stress play an important role in NAFLD development and progression. NAFLD affects one in three adults and one in 10 children/adolescents in the United States. Mortality in patients with NAFLD is significantly higher than in the general population of same age and gender with liver-related complications. Lifestyle intervention may improve NAFLD, but medications that increase insulin sensitivity and the anti-oxidant defenses in the liver deserve evaluation in carefully controlled trials.  相似文献   

5.
目的探讨非酒精性脂肪性肝病(NAFLD)患者糖代谢与血清脂联素关系。方法选择2010年10月至2011年11月我院140例门诊确诊的非酒精性脂肪肝病患者,根据糖耐量结果,分为糖耐量正常组及糖代谢异常组,并选择50例健康体检者为对照组,测定所有体检者的IBM、血清谷丙转氨酶(ALT)水平,应用酶联免疫吸附法(ELISA)测定血清中脂联素含量。结果①NAFLD患者糖代谢异常的发生率高达55.7%。②NAFLD患者血清脂连素水平均低于健康对照组,其中合并糖代谢异常者下降更明显,肝功能损伤也更严重。结论血清脂联素水平、糖代谢异常与NAFLD发生、发展密切相关。OGTT及血清脂联素检测,有望作为临床评估NAFLD程度及判断预后的一项指标。  相似文献   

6.
ABSTRACT

Objective: Considering the high prevalence of nonalcoholic fatty liver disease and based on the evidence about the role of dietary cholesterol in liver inflammation, and also with regard to the effect of phytosterols on the metabolism of cholesterol, we aimed at exploring the therapeutic potential of phytosterol supplementation against nonalcoholic fatty liver disease.

Method: Thirty-eight patients with nonalcoholic fatty liver disease were randomly divided into two groups: The phytosterol group (n = 19) received a 1.6-g phytosterol supplement daily and the control group (n = 19) received 1.6 g starch daily as placebo for an 8-week period. Blood samples of all patients were taken at baseline (week 0) and at the end of the study (week 8) for measurement of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin.

Results: Phytosterol supplementation significantly improved the levels of low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, and tumor necrosis factor alpha compared to the placebo group. On the other hand, there were no significant differences between the two groups in total cholesterol, triglycerides, high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, ratios of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol, gamma-glutamyl transferase, interleukin 6, high-sensitivity C-reactive protein, adiponectin, and leptin.

Conclusions: The present study suggested that daily consumption of 1.6 g phytosterols efficiently lowers low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, and tumor necrosis factor alpha in patients with nonalcoholic fatty liver disease.  相似文献   

7.
Objective: There is a promising perspective regarding the potential effect of resveratrol in preventing and treating metabolic disturbances similar to that of calorie restriction. The aim of this study was to evaluate the effects of calorie-restricted (CR) diet on metabolic parameters and then to investigate whether resveratrol supplementation has beneficial effects similar to CR diet in patients with nonalcoholic fatty liver disease (NAFLD).

Methods: This randomized controlled clinical trial was conducted in 90 patients with NAFLD (males and females) aged 20 to 60 years with body mass index (BMI) ranging from 25 to 35 kg/m2. Participants were assigned to one of three intervention groups as follows: The CR diet group (n = 30) received a prescribed low-calorie diet, the resveratrol group (n = 30) received 600 mg pure trans-resveratrol (2 × 300 mg) daily, and the placebo group (n = 30) received placebo capsules (2 × 300 mg) daily for 12 weeks. Fasting blood samples, anthropometric measurements, and dietary intake and physical activity data were collected for all participants at baseline and at the end of the trial.

Results: CR diet significantly reduced weight (by 4.5%); BMI; waist circumference; waist-to-hip ratio; and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles in participants compared to resveratrol and placebo (all p < 0.05). Significant reductions in weight (by 1.1%) and BMI were found in the resveratrol group compared to the placebo group (p < 0.05). ALT, AST, and lipid profiles did not change significantly in the resveratrol group (all p > 0.05). No significant changes were seen in hepatic steatosis grade, serum glycemic parameters, and high-density lipoprotein cholesterol and sirtuin-1 levels in any group (all p > 0.05).

Conclusions: CR diet with moderate weight loss has favorable effects on NAFLD, and resveratrol supplementation induced weight loss but failed to mimic other aspects of CR diet. Future studies are warranted to evaluate the long-term and dose-dependent effects of resveratrol on metabolic diseases.  相似文献   


8.
Objective: Nonalcoholic fatty liver disease (NAFLD) is a condition defined by exceeding triglycerides accumulation in the liver. The condition can develop into fibrosis, cirrhosis, and hepatocellular carcinoma. Considering the ever-increasing prevalence of NAFLD, the aim of the present study was to investigate the effects of probiotic supplementation on glycemic and inflammatory indices in patients with NAFLD.

Methods: This randomized clinical trial was conducted on 42 patients with NAFLD who had been referred to a gastroenterology clinic. Subjects in the intervention and control groups consumed 2 capsules/day probiotic or placebo, respectively, for 8 weeks. Fasting blood sugar (FBS), insulin, insulin resistance, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) were measured at baseline and at the end of the study.

Results: Means of FBS, insulin, insulin resistance, and IL-6 were significantly different between groups after intervention (p < 0.05), whereas TNF-α was not significantly modified (p > 0.05). In the probiotic group, insulin, insulin resistance, TNF-α, and IL-6 decreased significantly at the end of the study compared to the beginning of study.

Conclusion: Considering the effects of probiotic supplementation on the reduction of glycemic and inflammatory indices in patients with NAFLD, consumption of probiotics is recommended as a complementary therapy in these patients.  相似文献   


9.
Abstract

Background: In animal models, histological and biochemical changes are observed in response to choline deficiency. It is unclear whether dietary choline is linked to non-alcoholic fatty liver disease (NAFLD).

Objective: We examined the link among liver tests, fatty liver index (FLI), and choline consumption. Furthermore, we evaluated the impact of adiposity on this association.

Method: The National Health and Nutrition Examination Survey (NHANES) was used to obtain data on choline intake and liver function biomarkers. Masked variance and weighting methodology were performed to account for the complex NHANES data.

Results: Of the 20,643 participants, 46.8% were men and 45.6% had NAFLD (defined as United States FLI ≥30). In a fully adjusted model (for demographic, dietary, and clinical factors), a significant negative association was found between FLI and choline consumption (β?=??0.206, p?<?0.001). Participants in the highest quartile (Q4) of choline intake had a 14% lower risk of NAFLD compared with those in the first quartile (Q1). This link was stronger for postmenopausal women; women in Q4 had a 26% lower risk of NAFLD compared with those in Q1. Body mass index (BMI) strongly moderated the link between FLI and choline intake. For example, when choline consumption increased from low (272?mg/d) to high (356?mg/d), FLI decreased from 79.3 to 74.1 in the low BMI category (mean BMI =?22.1?kg/m2) and from 32.1 to 20.6 in the high BMI category (mean BMI =35.9?kg/m2).

Conclusions: Our results suggest the presence of a reverse significant association between choline intake and risk of NAFLD. Furthermore, BMI was shown to mediate this relationship since changes in FLI, in relation to choline consumption, were more pronounced in participants with a higher BMI.  相似文献   

10.
目的探讨在2型糖尿病(T2DM)合并非酒精性脂肪性肝病患者中检测空腹血清同型半胱氨酸(tHCY)及血清铁蛋白(sF)的临床意义。方法将195例T2DM患者分为单纯糖尿病组(A组)83例,合并非酒精性脂肪肝组(B组)60例及合并非酒精性脂肪性肝炎组(C组)52例,分别测定身高,体重,抽空腹血检查tHCY、SF、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL—C)、低密度脂蛋白胆固醇(LDL-C)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)、糖化血红蛋白(HbA1C)、空腹血糖(FBG)及空腹胰岛素(FINS)等。计算体质指数(BMI)及胰岛素抵抗指数(HOMA—IR)。结果B组BMI、TG、TC、LDL~C、ALT、AST、GGT、tHCY、SF、FINS、HOMA—IR均明显高于A组(P〈O.05),C组均明显高于B组(P〈0.05)。而B组HDL—C均明显低于A组(P〈0.05),C组均明显低于B组(P〈0.05)。3组间HbA-c、FBG及年龄差异无统计学意义。Pearson相关分析结果显示,tHCY与BMI、TG、TC、LDL—C、FINS、HOMA—IR呈显著正相关(P〈0.05),与HDL—C呈显著负相关(P〈0.05);SF与BMI、TG、TC、LDL—C、FINS、HOMA—IR呈显著正相关(P〈0.05),与HDL—C呈显著负相关(P〈0.05)。结论tHCY及SF是T2DM合并非酒精性脂肪性肝病的危险因素,并且与BMI、TG、TC、I.DL—C、FINS、HOMA—IR、HDL—C水平具有相关性。  相似文献   

11.
Increased reactive oxidative stress, lipid peroxidation, inflammation, and fibrosis, which contribute to tissue damage and development and progression of nonalcoholic liver disease (NAFLD), play important roles in microcirculatory disorders. We investigated the effect of the modulatory properties of simvastatin (SV) on the liver and adipose tissue microcirculation as well as metabolic and oxidative stress parameters, including the advanced lipoxidation end product–receptors of advanced glycation end products (ALE-RAGE) pathway. SV was administered to an NAFLD model constructed using a high-fat–high-carbohydrate diet (HFHC). HFHC caused metabolic changes indicative of nonalcoholic steatohepatitis; treatment with SV protected the mice from developing NAFLD. SV prevented microcirculatory dysfunction in HFHC-fed mice, as evidenced by decreased leukocyte recruitment to hepatic and fat microcirculation, decreased hepatic stellate cell activation, and improved hepatic capillary network architecture and density. SV restored basal microvascular blood flow in the liver and adipose tissue and restored the endothelium-dependent vasodilatory response of adipose tissue to acetylcholine. SV treatment restored antioxidant enzyme activity and decreased lipid peroxidation, ALE-RAGE pathway activation, steatosis, fibrosis, and inflammatory parameters. Thus, SV may improve microcirculatory function in NAFLD by downregulating oxidative and ALE-RAGE stress and improving steatosis, fibrosis, and inflammatory parameters.  相似文献   

12.
We determined the relationships between metabolic score for IR (METS-IR), triglyceride-glucose (TyG) index, and homeostatic model assessment for IR (HOMA-IR) and incident advanced liver fibrosis (ALF) and assessed the abilities of the three IR indicators to predict ALF in patients with non-alcoholic fatty liver disease (NAFLD) in adults with NAFLD who were aged 40–69 years old. Among 2218 participants with NAFLD at baseline, the areas under the receiver operating characteristic curve for predicting ALF of the METS-IR was 0.744 (0.679–0.810), significantly higher than that of TyG index (0.644 (0.569–0.720)) or that of HOMA-IR (0.633 (0.556–0.710)). Among 1368 patients with NAFLD and without ALF at baseline, 260 (19.0%) patients with NAFLD progressed to ALF during the 16-year follow-up period. Multivariable Cox proportional hazard regression analysis revealed that the adjusted hazard ratio (95% confidence interval) for incident ALF in the highest tertiles of METS-IR, TyG index, and HOMA-IR compared with the lowest tertile of each IR indicator were 0.5 (0.36–0.91), 0.7 (0.49–1.00), and 1.01 (0.71–1.42), respectively. METS-IR was inversely associated with ALF in patients with NAFLD, which cautiously suggests that the risk of ALF may need to be evaluated when metabolic parameters improve in individuals with NAFLD.  相似文献   

13.
目的 研究非酒精性脂肪肝模型大鼠的血清C-反应蛋白(CRP)水平变化,探讨其与肝功能之间的关系.方法 实验大鼠分为模型组(HF)、模型恢复组(FC)和对照组(NC).NC组采用基础饲料喂养,HF组采用高脂饲料喂养,FC组高脂喂养8周后改基础饲料喂养.模型建立后取大鼠空腹血测定血清肝酶系、血脂及CRP水平,肝脏标本作组织病理学检查.结果 高脂饲料喂养8周后,大鼠肝脏出现典型脂肪变性及炎症细胞浸润;12周后有重度脂肪变性伴大量炎症细胞浸润.HF组血清肝酶系(ALT、AST)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)水平均较NC组升高,血清CRP水平(0.43±0.14)mg/L亦高于NC组(0.14±0.08)mg/L.采取饮食控制的FC组肝脏病变程度减轻,ALT、AST、TC和HDL-C水平下降,CRP水平亦较HF组降低(0.21±0.14)mg/L.相关性分析显示脂肪肝大鼠的血清CRP水平与ALT水平正相关(r=0.56,P<0.05).结论 非酒精脂肪肝模型大鼠血清CRP水平升高,并与肝功能指标(ALT水平)正相关,CRP可能是非酒精性脂肪肝的预测因素之一.  相似文献   

14.
肥胖儿童脂肪肝与其糖脂代谢的初步探讨   总被引:2,自引:0,他引:2  
目的探讨上海市部分肥胖儿童肥胖程度与脂肪肝发生率的关系以及这些儿童血清部分糖脂代谢指标改变。方法随机筛取1999年至2000年门诊体检儿童100名,同期内分泌门诊就诊单纯性肥胖儿童43名,年龄6~13岁,性别不限,无明显器质性疾病。收集病史资料,测量身高体重,B超检查肝脏,测定血清瘦素、C肽、空腹血糖、血脂(甘油三酯,胆固醇,高密度脂蛋白胆固醇,低密度脂蛋白胆固醇)。按体质指数(BMI)值和有无脂肪肝情况将这些儿童分组。比较各组血清瘦素、C肽、空腹血糖、血脂值有无差异。结果内分泌门诊就诊的肥胖儿童中脂肪肝发生率为13/43,最早发生脂肪肝年龄为7岁。脂肪肝组儿童BMI值明显高于非脂肪肝组儿童(P<0.05)。脂肪肝与非脂肪肝组肥胖儿童血脂、空腹血糖、C肽、瘦素无明显差异(P>0.05)。中重度肥胖儿童血清瘦素、C肽、空腹血糖、血脂(甘油三酯)明显升高(P<0.05)。结论中重度肥胖儿童已发生糖脂代谢紊乱,其中近1/3并发脂肪肝。BMI值可能有助于判断儿童脂肪肝的发生。  相似文献   

15.
目的观察营养干预对肝炎后非酒精性脂肪肝(NAFL)的改善。方法52例肝炎后NAFL患者随机分为观察组(n=29)和对照组(n=23),两组给予相同的药物治疗,观察组另给予为期6个月的营养干预,对照组则自主选择食物。结果观察组经营养干预后人体各项测量值,天冬氨酸转移酶、丙氨酸转移酶、甘油三脂、血糖和胆固醇、低密度脂蛋白水平明显低于对照组(P<0.05~0.01),高密度脂蛋白较对照组明显上升(P<0.05),而总胆红素的水平两组间差异无显著性。B超结果显示,观察组干预后有17例患者脂肪肝得到改善,两组相比差异有显著性(P<0.01)。结论合理的营养干预可以稳定肝炎病情,并使患者脂肪肝得到改善。  相似文献   

16.
Nonalcoholic fatty liver disease (NAFLD) is an emerging global health concern. It is the most common form of chronic liver disease in Western countries, affecting both adults and children. NAFLD encompasses a broad spectrum of fatty liver disease, ranging from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH), and is strongly associated with obesity, insulin resistance, and dyslipidemia. First-line therapy for NAFLD includes weight loss achieved through diet and physical activity. However, there is a lack of evidenced-based dietary recommendations. The American Diabetes Association’s (ADA) recommendations that aim to reduce the risk of diabetes and cardiovascular disease may also be applicable to the NAFLD population. The objectives of this review are to: (1) provide an overview of NAFLD in the context of insulin resistance, and (2) provide a rationale for applying relevant aspects of the ADA recommendations to the nutritional management of NAFLD.  相似文献   

17.
Objective: Nonalcoholic fatty liver disease (NAFLD) is considered by some to be the hepatic manifestation of the metabolic syndrome (MS). However, others believe NAFLD is a distinct entity that actually initiates MS. Whichever is true, a definite linkage exists between both is generally accepted based upon the frequency of common occurrence and realization that insulin resistance (IR) is and realization that. The objective is to better understand the relationship between NAFLD and MS. Specifically, is there any concrete evidence that development of NAFLD precedes MS or vice versa? Another goal was to better comprehend capabilities of circulating aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) and their ratio used commonly for diagnosis of NAFLD.

Methods: Data from 288 participants with fasting blood glucose (FBG) levels below the diabetic level (<125 mg/dL) and AST and ALT values in the normal range (<40 U/L) were examined. Correlations between ALT and AST and their ratio as independent variables with a variety of metabolic parameter were evaluated and compared.

Results: Like FBG, many significant positive correlations among glucose–insulin indices, body composition, blood pressure, dyslipidemias, and inflammation were discovered using ALT, and less so with AST, as the independent variable. In some cases, even stronger correlations in a negative direction with IR and MS were found with the ratio AST/ALT. Corroboration occurred when values in the lowest and highest quartiles of ALT and AST/ALT readings showed appropriate statistically significant differences. Conclusions: The findings here suggest that both NAFLD and the MS very early in development have a common inciting mechanism(s)—most likely IR. Accordingly, the early concurrent temporal results are consistent with the concept that NAFLD is a hepatic manifestation of the IR associated with the MS. They do not exclude the possibility that once some liver functional adjustments take place, several aspects of the MS are bolstered further, perhaps via intensified heightening of IR.  相似文献   

18.
PURPOSE: To evaluate whether the presence of metabolic syndrome (MS) in obese adolescents is associated with other comorbidities of obesity METHODS: A total of 85 obese teens (70% female and 30% male) with fasting insulin >25 microU/ml and family history of type 2 diabetes mellitus and/or acanthosis nigricans were studied. Mean age was 15.8 +/- 1.7 years and body mass index (BMI) was 39.3 +/- 6.6 kg/m(2). Of the subjects, 54% were Hispanic and 35% black, 5% white, 5% American Indian, and 1% Asian. Laboratory analysis included fasting lipids, glucose, gamma-glutamyl transpeptidase (GGT), and oral glucose tolerance testing. Additional liver transaminase levels were determined and liver ultrasound (US) was performed to evaluate the presence and severity of fatty liver. RESULTS: All subjects met MS criteria for children for waist circumference, 49% for blood pressure, 54% for high-density lipoprotein, 54% for triglycerides, and 20% for impaired fasting glucose (IFG) or impaired glucose tolerance [IGT]). In all, 47 subjects had three or more MS criteria. BMI was no different between groups with and without MS. Subjects with three or more MS criteria were more likely to have IGT (p = .004), elevated alanine aminotransferase (p = .039), elevated GGT (p = .036), fatty liver on US (p < .001), and more severe fatty liver (p = .001). CONCLUSIONS: Abnormal glucose regulation and evidence of nonalcoholic fatty liver disease (NAFLD) were more common in subjects meeting three criteria for MS than in those meeting fewer criteria. The identification of MS provides value to the primary care provider. Those patients meeting criteria for MS should be evaluated for glucose intolerance and NAFLD.  相似文献   

19.
目的探讨非酒精性脂肪性肝病(NAFLD)危险因素。方法对本院资料完整的1309例体检者资料进行研究。结果1309人中非酒精性脂肪性肝病的总患病率为22.61%,男性患病率约为女性的2.66倍。结论增强非酒精性脂肪性肝病特点的认识对及时诊治,防止进一步发展十分必要。  相似文献   

20.
目的探讨非酒精性脂肪性肝病(NAFLD)危险因素。方法对本院资料完整的1309例体检者资料进行研究。结果1309人中非酒精性脂肪性肝病的总患病率为22.61%,男性患病率约为女性的2.66倍。结论增强非酒精性脂肪性肝病特点的认识对及时诊治,防止进一步发展十分必要。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号